Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Clinical Centers (U01 Clinical Trial Required)

National Institutes of Health · United States government procurement

GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

$3.0M
Est. Value
October 09, 2026
Response Due
Active
Status

Opportunity Overview

<p>This Notice of Funding Opportunity (NOFO) invites applications from clinical centers to participate in a consortium to test anti-obesity medication (AOM) treatment strategies for youth with obesity that maximize benefits and minimize risks of AOM use. Such intervention strategies should support the promotion of healthy growth and development; adequate nutritional status/intake, healthy eating and physical activity behaviors; mental health and well-being (e.g., body image, self-esteem, mood, etc.), and quality of life and be feasible to implement in clinical care settings. Priority areas include testing strategies to determine optimal developmental stage for AOM initiation, rate and amount of weight loss, AOM class, dose, frequency, and duration, and content and intensity of adjunct lifestyle therapies that may be imperative to ensure normal psychological and physical development and to potentially avoid lifelong dependence on AOMs.&nbsp; Investigators should also evaluate potential predictors of response/ nonresponse to various treatment strategies under evaluation. The consortium may conduct independent or multicenter trials but will collaborate on the development of protocols, use of common measures and data elements, use of a central laboratory and standardized procedures to collect data and biospecimens, and data analyses and manuscripts.&nbsp; &nbsp;</p>

This is one of 123 active United States Pharmaceuticals opportunities most of your competitors will never see.

Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start Free

Solicitation Details

Issuing agencyNational Institutes of Health
CountryUnited States
CategoryPharmaceuticals
Estimated value$3.0M
NAICS93.847
PublishedJune 08, 2026
Procurement stageRequest for Proposal (RFP)
Response dueOctober 09, 2026
StatusOpen — accepting responses
Official sourceView original notice
Last verifiedAugust 12, 2026

Source: U.S. Government (Simpler.Grants.gov) — public domain. Not affiliated with or endorsed by the United States Government.

Related Opportunities in United States

PPVG GEN V Award
National Retardant
PPVG GEN V AWARD SPE2DX25D8000
Febuxostat National Contract
Ziprasidone Capsules
Hydrocodone Acetaminophen
Olanzapine SPE2D2-25-D-0011 Award
Olopatadine HCL 0.1% Ophthalmic Solution

See every United States Pharmaceuticals opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free United States Pharmaceuticals intelligence report in your inbox

A personalized report on United States Pharmaceuticals opportunities, emailed in 5-10 minutes. One per month, no account needed.